HOME >> BIOLOGY >> NEWS
Antibody therapy can increase the effectiveness of cancer vaccine, early studys

BOSTON The benefit of some cancer vaccines may be boosted by treating patients with an antibody that blocks a key protein on immune system T cells, according to a small, preliminary study led by researchers at Dana-Farber Cancer Institute and Brigham and Women's Hospital.

The study, to be published online on April 1 in the Early Edition of the Proceedings of the National Academy of Sciences (www.pnas.org), tested the effect of a single injection of the antibody MDX-CTLA4 in nine patients who had previously been treated with cancer vaccines for either metastatic melanoma or metastatic ovarian cancer. The result, in every patient who had received a particular kind of vaccine, was widespread death of cancer cells and an increase in the number of immune system cells within the tumors evidence of a potent immune system attack.

"This study makes a strong case that combined immunotherapy consisting of a vaccine and antibodies can elicit a potent immune response to some types of tumors in patients," says the study's senior author, Glenn Dranoff, MD, of Dana-Farber.

The technique was inspired by the laboratory work of study co-author James Allison, PhD, a Howard Hughes Medical Institute investigator at the University of California, Berkeley. He and his colleagues discovered that a protein, or antigen, called CTLA-4 on T cells restrains the immune system from attacking cancer cells. In a series of laboratory and animal experiments, Allison's team showed that combining a cancer vaccine with an antibody able to block CTLA-4 resulted in an especially potent immune attack on tumors.

On the basis of those findings, Dranoff and his colleagues launched a Phase I clinical trial of the technique in a small group of patients. Because animal experiments had indicated that giving MDX-CTLA4 in combination with a vaccine might prompt the immune system to attack some normal cells, researchers decided to give the ant
'"/>

Contact: Bill Schaller
william_schaller@dfci.harvard.edu
617-632-5357
Dana-Farber Cancer Institute
1-Apr-2003


Page: 1 2 3

Related biology news :

1. Antibody coated stent a breakthrough in cardiovascular treatment
2. The spice of life: Antibody cocktail targets deadly foodborne germs
3. Dana-Farber launches NFCR Center for Therapeutic Antibody Research and Engineering
4. Antibody Revolution Targets STDs, Stomach Viruses, Common Cold
5. Novel Two-Antibody Strategy To Fight Cancer Awarded Patent
6. Targeted therapy knocks out pediatric brain cancer in mice
7. New anti-inflammatory strategy for cancer therapy identified by UCSD researchers
8. Columbia research to examine gene influence on severity of peridontal disease, therapy response
9. Case for IBD combination therapy comes from research at Baylor, MIT and Hebrew University
10. The search for a kinder, gentler chemotherapy
11. Embryonic stem cell therapy shows steady benefits in rebuilding infarcted heart

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/6/2019)... FRANCISCO (PRWEB) , ... February 04, 2019 , ... ... of a new Explorer™ story which provides insights to help individuals understand how ... to decreased cardiovascular wellness. , After individuals eat foods that contain choline ...
(Date:2/2/2019)... ... February 01, 2019 , ... uBiome, ... Testing Laboratories by A2LA, which establishes requirements for medical laboratories to demonstrate competence ... is already CLIA-licensed as well as College of American Pathologists (CAP)-accredited, a designation ...
(Date:1/24/2019)... ... 23, 2019 , ... rHEALTH LLC, an innovative digital health ... the United States Patent and Trademark Office (USPTO) for U.S. Patent Application No. ... This application covers the addition of a length scale to hydrogel microparticles. ...
Breaking Biology News(10 mins):
(Date:1/15/2019)... ... 15, 2019 , ... Personalized treatment plans may extend life expectancy for early-stage ... new study published in the journal Radiology. , Kidney, or renal, tumors are ... surgical procedure in which the tumor and part of the kidney are removed. However, ...
(Date:1/11/2019)... ... 11, 2019 , ... Drawing on over 22 years of software development expertise, ... EST will explore some of the key lessons that have driven customer satisfaction with ... multiple vendors, and find out how to ensure that you continue to be able ...
(Date:1/10/2019)... (PRWEB) , ... January 08, 2019 , ... VGI Medical ... has become a leader in bringing innovation to the market including VerteLoc, CerLoc, SiJoin ... the facet joint by utilizing a unique patented dual geometric design to limit motion ...
(Date:1/7/2019)... ... 07, 2019 , ... Kainos Medicine Inc. today announced that ... code-named "KM-819." KM-819 is an orally active small molecule that is a ... , This Phase 1 randomized, double-blind, placebo-controlled dose-escalation study was to evaluate ...
Breaking Biology Technology:
Cached News: